📋 Indications & Clinical Dosage
*Prevention of atherothrombotic events in patients suffering from myocardial infarction (for less than 35 days), ischaemic stroke (from day 7 to 6 months) or established peripheral artery disease, in combination with aspirin in non-ST segment elevation acute coronary syndrome (unstable angina or non-C-Wave Myocardial Infarction):*
Adults: 1 tab daily.
CHILDREN: Not recommended.
⛔ Contraindications
Do not initiate therapy within first few days after MI. PTCA (stenting), CABG acute ischaemic stroke of less than 7 days, hypoprothrombinaemia, severe hepatic impairment, bleeding dis-orders, active bleeding such as peptic ulcer or intracranial haemorrhage.
⚠️ Precautions & Warnings
Renal or hepatic impairment, moderate hepatic impairment, surgery, risk of bleeding and blood dyscrasias; perform blood counts, unusual bleeding, history of bronchospasm, dyspepsia.
🔄 Drug Interactions
Anticoagulants, glycoprotein lib/Iiia inhibitors, thrombolytics, NSAIDs, hypoglycaemics, phenytoin, sodium valproate, uricosuric agents, methotrexate, sulphonamides, spironolactone, cor-ticosteroids, antacids.
⚠️ Adverse Reactions / Side Effects
Bleeding manifestation, GI upset, skin reactions, , nervous system, hepatic, biliary or, haematological disorders. Rare: thrombotic thrombocyt penic purpura
🤰 Pregnancy & Lactation Safety
Pregnancy Risk:
Contraindicated
Lactation / Breastfeeding:
Not recommended.
📚 Official Regulatory & Clinical References
- Drug Regulatory Authority of Pakistan (DRAP): Drug Registration, S.R.O. Price Gazettes & National Essential Medicines List (NEML).
- World Health Organization (WHO): Collaborating Centre for Drug Statistics Methodology (ATC/DDD Index).
- Formulary Standards: British National Formulary (BNF) & Pakistan National Formulary (PNF) guidelines.